We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Pluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6%
Pluristem Therapeutics, Inc. was a big mover last session, as its shares rose almost 12% on the day. The upside was driven by the release of positive data from studies of the company’s PLX-PAD cells in the treatment of Duchenne muscular dystrophy. This also move led to far more shares changing hands than in a normal session. Yesterday’s rally reverses the downtrend for the company, as the stock is now down almost 13% in the past one-month time frame.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Pluristem Therapeutics has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
PLURISTEM THERA Price
PLURISTEM THERA Price | PLURISTEM THERA Quote
Another favorably ranked stock in the biomedical space is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , sporting a Zacks Rank #1 (Strong Buy).
Is PSTI going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>